Remarkably, breast cancer CTCs that express the stem cell marker ALDH1 have been suggested to be involved in metastatic disease progression, with one study showing that 76% of CTC positive patients carried ALHD1 positive CTCs23, 24. This evidence concerns the gene ALDH1A1 and breast carcinoma.